Broad spectrum vasopressors: a new approach to the initial management of septic shock?

Lakhmir S. Chawla1,2*, Marlies Ostermann3, Lui Forni4,5 and George F. Tidmarsh2,6

Abstract

The mainstay of hemodynamic treatment of septic shock is fluid resuscitation followed by vasopressors where fluids alone are insufficient to achieve target blood pressure. Norepinephrine, a catecholamine, is the first-line vasopressor used worldwide but given that all routinely used catecholamines target the same adrenergic receptors, many clinicians may add a non-catecholamine vasopressor where refractory hypotension due to septic shock is present. However, the timing of this additional intervention is variable. This decision is based on three key factors: availability, familiarity, and safety profile. In our opinion, further consideration should be potential vasopressor response because following appropriate volume resuscitation, the response to different vasopressor classes is neither uniform nor predictable. Critically ill patients who are non-responders to high-dose catecholamines have a dismal outcome. Similarly, patients have a variable response to non-catecholamine agents including vasopressin and angiotensin II: but where patients exhibit a blood pressure response the outcomes are improved over non-responders. This variable responsiveness to vasopressors is similar to the clinical approach of anti-microbial sensitivity. In this commentary, the authors propose the concept of "broad spectrum vasopressors" wherein patients with septic shock are started on multiple vasopressors with a different mechanism of action simultaneously while the vasopressor sensitivity is assessed. Once the vasopressor sensitivities are assessed, then the vasopressors are 'de-escalated' accordingly. We believe that this concept may offer a new approach to the treatment of septic shock.

Keywords: Septic shock, Catecholamines, Vasopressin, Angiotensin II, Sensitivity

Background

Sepsis remains the most common cause of vasodilatory shock worldwide. International consensus guidelines describe specific recommendations regarding treatment. These include the timing of important interventions comprising blood culture collection, initiation of broad-spectrum antibiotics, blood glucose targets, use of steroids, and restoration of optimal hemodynamic status [1]. The mainstay of treatment with regard to restoring and maintaining optimal hemodynamic status is rapid and appropriate fluid bolus therapy (FBT) which, if insufficient, is followed by vasopressor therapy to maintain an acceptable mean arterial pressure (MAP). Despite this approach being a cornerstone of therapeutic guidelines, there is a lack of high-quality evidence demonstrating a survival benefit associated with the use of one vasopressor over another [2]. Although current consensus guidelines recommend norepinephrine as the first-line vasopressor, both selection and timing of second-line therapy in refractory hypotension due to septic shock is highly variable. Indeed, in a recent survey of practice, only 14% of respondents cited a predefined dose of the first agent as the stimulus for additional therapy [3, 4]. Selection of the vasopressor agent is also variable and further complicated by the recent data related to a "new" vasopressor, angiotensin II, which is currently only available in the USA [5, 6].

Main text

Given that all routinely used catecholamines target the same adrenergic receptors, most clinicians are inclined to add a non-catecholamine vasopressor to treat patients...
with refractory hypotension due to septic shock, a decision based on three key factors: availability (a relatively rigid constraint), familiarity (often governed by previous practice), and safety profile. In our opinion, further consideration should be potential vasopressor response. Following appropriate volume resuscitation, the response to different vasopressor classes is neither uniform nor predictable. Furthermore, the responsiveness to a vasopressor may impact the outcome. Indeed, norepinephrine, recognized as the first-line vasopressor, often demonstrates a variable response which may be due to various factors which include pre-existing therapy/medications, genetics, the underlying pathophysiology of septic shock, and/or receptor responsiveness [7–10]. Both human and pre-clinical data demonstrate that septic shock impairs sympathetic modulation of the heart and vasculature [7]. In fact, septic shock patients who maintain adrenergic responsiveness have better outcomes [9]. Similarly, non-catecholamine vasopressors including vasopressin and angiotensin II can be affected by concomitant medications, genetics, and altered receptor responsiveness as a consequence of inflammation and sepsis [10–12]. The net effects of all of these parameters are difficult to compute at the bedside, but the key issue is whether responsiveness to a vasopressor impacts outcomes.

Non-responders to high-dose catecholamines have a dismal outcome [13]. In terms of non-catecholamine agents, less than 50% of patients demonstrate a MAP response to low-dose vasopressin with this group having a significantly better survival than those that fail

| Table 1: Outcomes Assessed by MAP Response to Vasopressin or Angiotensin II |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                  | Vasopressin [14] | Angiotensin II [6] |
| In-patient mortality (%)        | Responder 45% (n = 426) | Non-responder 55% (n = 512) | P value | Responder 69.9% (n = 114) | Non-responder 30.1% (n = 49) | P value |
| Catecholamine dose (mcg/kg/min) | 0.35 ± 0.25 | 0.33 ± 0.27 | 0.18 | 0.32 ± 0.32 | 0.53 ± 0.39 | 0.0002 |
| MAP (mmHg)                      | 69 ± 12 | 65 ± 12 | < 0.001 | 67.1 ± 5.21 | 64.8 ± 5.02 | 0.0087 |
| Steroids (%)                    | 58.9 | 62.5 | 0.26 | 55.3 | 57.1 | 0.8647 |
| Lactate (mmol/L)                | 4.0 ± 3.6 | 5.4 ± 4.8 | < 0.001 | 3.43 ± 2.43 | 5.80 ± 6.01 | 0.013 |
| SOFA score                      | 13 ± 4 | 12 ± 3 | 0.49 | 11.65 ± 2.78 | 12.06 ± 2.99 | 0.4313 |
| Age, years                      | 62 ± 14 | 61 ± 15 | 0.17 | 61.7 ± 15.32 | 63.1 ± 16.33 | 0.4278 |

Fig. 1: Survival probability by MAP response at hour 3 for patients in the ATHOS-3 trial
to respond [14] (Table 1). Similarly, approximately 70% of patients who receive angiotensin II have a MAP response. [6, 15] In a responder analysis, the ATHOS-3 study showed that a responder’s chance of survival is significantly better than that of patients who fail to respond to angiotensin II [6, 15] (Table 1, Fig. 1). It follows that in patients with septic shock, the choice of vasopressor should be governed by the patient’s likelihood of responding and the sensitivity to treatment. This notion is in keeping with current antimicrobial therapy paradigm wherein clinicians obtain cultures and start broad-spectrum antibiotics with the intention of de-escalating the antibiotics once the causative organism is identified.

Conclusion
We propose the notion of “broad spectrum vasopressors” wherein patients with septic shock are started on multiple vasopressors with a different mechanism of action simultaneously while the vasopressor sensitivity is assessed. Vasopressor sensitivity could be assessed by sequential removal of vasopressors or developing a vasopressor sensitivity panel. Once the vasopressor sensitivities are assessed, then the vasopressors are de-escalated accordingly. However, this concept is hampered by several issues. Firstly, there is currently no bedside test that predicts the blood pressure response to catecholamines, vasopressin, or angiotensin II. Secondly, not all of these vasopressors are currently available worldwide due to either a lack of regulatory approval or cost considerations. Thirdly, there are no prospective data supporting this approach. Despite these hurdles, we feel that this is a testable hypothesis: Does time to sensitive vasopressor response improve outcomes in septic shock? We suggest this is a question worth answering and may prove an essential approach in managing these critically ill individuals.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
LSC and GFT are both employees and stockholders of La Jolla Pharmaceutical Company. The other authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Veterans Affairs Medical Center, 3350 La Jolla Village Dr, San Diego, CA 92161, USA. 2La Jolla Pharmaceutical Company, San Diego, CA, USA. 3King’s College London, Guy’s & St Thomas’ Hospital, London, UK. 4Department of Clinical and Experimental Medicine, Faculty of Health Sciences, University of Surrey, Guildford, UK. 5Intensive Care Unit, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK. 6Stanford University School of Medicine, Palo Alto, CA 94305, USA.

Received: 12 March 2019 Accepted: 2 April 2019

References
1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. 2016. Intensive Care Med. 2017;43(3):304–77.
2. Gamper G, Havel C, Arrich J, Losert H, Pace NL, Mullner M, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;2:CD003709.
3. Abri l MK, Khanna AK, Kroll S, McNamara C, Handsides D, Busse LW. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data. J Crit Care. 2018;50:188–94.
4. Scheeren TWL, Bakker J, De Backer D, Annane D, Astar P, Boerma EC, et al. Current use of vasopressors in septic shock. Ann Intensive Care. 2019;9(1):20.
5. Ahmadnia E, Hail A, Ostermann M. Angiotensin in clinical practice. J Translat Med. 2019;17(1):71.
6. Sacha GL, Lam SW, Duggal A, Torbic H, Bass SN, Welch SC, et al. Predictors of response to fixed-dose vasopressin in adult patients with septic shock. N Engl J Med. 2017;377(5):419–30.
7. Annane D, Trabold F, Shansar T, Janin I, Blanc AS, Raphael JC, et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med. 1999;160(2):458–65.
8. Jones SR, Romano FD. Myocardial beta adrenergic receptor coupling to adenylate cyclase during developing septic shock. Circ Shock. 1990;33(4):51–61.
9. Kumar A, Schupp E, Bunnell E, Ali A, Milcarek B, Parrillo JE. Cardiovascular response to dobutamine stress predicts outcome in severe sepsis and septic shock. Crit Care. 2000;4(6):R35.
10. Maslove DM, Tang BM, McLean AS. Identification of sepsis subtypes in critically ill adults using gene expression profiling. Crit Care. 2012;16(5):R183.
11. Mederle K, Schweda F, Kattler V, Doblinger E, Miyata K, Hoehrl K, et al. The angiotensin II AT1 receptor-associated protein Arr1p is involved in sepsis-induced hypotension. Crit Care. 2013;17(4):R130.
12. Nakada TA, Russe1 JA, Boyd JH, MLAughlin L, Nakada E, Thair SA, et al. Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med. 2011;39(7):1641–8.
13. Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract. 2013;2013:654708.
14. Sacha GL, Lam SW, Duggal A, Torbic H, Bass SN, Welch SC, et al. Predictors of response to fixed-dose vasopressin in adult patients with septic shock. Ann Intensive Care. 2018;8(1):35.
15. Chawla LS, Busse L, Braha-Mitchell E, Davison D, Honiq J, Aotaibi Z, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534.